Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 4:10:123-139.
doi: 10.2147/DMSO.S130834. eCollection 2017.

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Philip A Levin  1 , Hiep Nguyen  2 , Eric T Wittbrodt  2 , Seoyoung C Kim  3
Affiliations
Review

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Philip A Levin et al. Diabetes Metab Syndr Obes. .

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety.

Objective: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed.

Methods: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D.

Results: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings.

Conclusion: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D.

Keywords: antidiabetic drugs; randomized controlled trials; retrospective; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Disclosure PA Levin has received grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. He is a consultant for AstraZeneca, Novo Nordisk, and Sanofi, and a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lily, GlaxoSmithKline, Janssen, Novo Nordisk, and Sanofi. H Nguyen was an employee of AstraZeneca at the time this review was conceived and drafted. ET Wittbrodt is an employee of AstraZeneca. SC Kim has received research grants to the Brigham and Women’s Hospital from Astra-Zeneca, Bristol-Myers Squibb, Genentech, Lilly, and Pfizer. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA flow diagram. Abbreviation: GLP-1RA, glucagon-like peptide-1 receptor agonist.
Figure 2
Figure 2
Efficacy of glucose-lowering treatments in type 2 diabetes. Changes from baseline in (A) glycated hemoglobin (HbA1c), (B) fasting glucose (FG), and (C) body weight (BW) in prospective studies comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) with other oral glucose-lowering therapies and changes from baseline in (D) HbA1c, (E) FG, and (F) BW in prospective studies comparing GLP-1RAs with insulin products. Abbreviation: DPP-4, dipeptidyl peptidase-4.
Figure 3
Figure 3
Comparison of efficacy of GLP-1RAs with other glucose-lowering treatments in type 2 diabetes. General trends in glycemic parameters and body weight (BW) in comparative trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other glucose-lowering therapies. The total number of studies includes studies that reported these parameters. Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; FG, fasting glucose; HbA1c, glycated hemoglobin; SU, sulfonylurea; TZD, thiazolidinedione.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Diabetes Association Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S1–S93. - PubMed
    1. International Diabetes Federation IDF Diabetes Atlas. 7th Ed. 2015. [Accessed January 31, 2017]. Available from: http://www.diabetesatlas.org/resources/2015-atlas.html.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. - PMC - PubMed
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149. - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. - PMC - PubMed

LinkOut - more resources

-